Halozyme Therapeutics (NASDAQ:HALO) is a biotechnology firm focused on developing innovative oncology therapies and drug-delivery solutions. Specializing in its proprietary enzyme technology, the company aims to improve the absorption, distribution, metabolism, and excretion (ADME) properties of other drugs. Halozyme's key projects revolve around the ENHANZE® drug delivery technology, which allows for subcutaneous administration of biologic drugs that would otherwise require intravenous delivery. This technology not only enhances patient convenience and compliance but also has the potential to significantly reduce healthcare costs. The company's objectives are centered on expanding the use of its ENHANZE® technology through partnerships with leading pharmaceutical companies, developing its own pipeline of novel cancer treatments, and achieving global recognition for its contributions to improving therapeutic outcomes.